WO2020130172A1 - 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 - Google Patents
오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2020130172A1 WO2020130172A1 PCT/KR2018/016129 KR2018016129W WO2020130172A1 WO 2020130172 A1 WO2020130172 A1 WO 2020130172A1 KR 2018016129 W KR2018016129 W KR 2018016129W WO 2020130172 A1 WO2020130172 A1 WO 2020130172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- proxin
- amyloid
- test
- administration
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a composition for preventing or treating cognitive improvement, dementia and hyperactivity disorder, which includes the extract of quince and proxin as active ingredients.
- Dementia cognitive ability, or memory loss can be said to be a "syndrome" in which remarkable difficulties in maintaining social and daily life occur mainly due to temporary or persistent damage to the brain nerve due to medical and neurological causes.
- Alzheimer's type dementia accounts for the majority of people with dementia.
- the mechanism of development of Alzheimer's dementia is not yet clear, but the toxicity of the neurotoxic protein ( ⁇ -amyloid protein) deposited in brain lesions has been suggested as the most important cause.
- Patients with dementia mainly show a marked decrease in function of various neurotransmitter systems in the cerebral cortex and cerebral limbic system and a decrease in the function of cerebral energy metabolism.
- AD' Alzheimer's Disease
- acetylcholine acetylcholine, hereinafter abbreviated as'ACh'
- glutamic acid glutamic acid
- neuropeptide neuropeptide
- monoamine systems neurotransmitters function.
- AD Alzheimer's Disease
- AD neurocytotoxic effect induced by the ⁇ -amyloid peptide
- the mechanism of development of AD due to the elimination of hippocampal neurons through the accumulation of germ spots out of the cells of the ⁇ -amyloid peptide is the main of AD It is believed to be one of the causes.
- AChE-inhibiting drugs are most effective when the cholinergic nerve is not functionally impaired, and the efficacy of these drugs decreases with the decline in cholinergic nerve function, so it is effective only in the early stages of mild or moderate senile dementia, most of which are peripheral It exhibits cholinergic side effects of nerves, half-life is too short, severe side effects such as liver toxicity, and especially 9-amino-1,2,3,4-tetrahydroacridine (THA), an active ingredient of Cognex Although it shows signs of improvement in perception when administered orally, it is not widely used because it has serious side effects such as tremor, dizziness, and liver toxicity.
- TAA 9-amino-1,2,3,4-tetrahydroacridine
- ADHD attention deficit hyperactivity disorder
- the present invention solves the above problems and was devised by the necessity of the above, the object of the present invention is to provide a novel composition for preventing or treating dementia (AD).
- AD dementia
- Another object of the present invention is to provide a composition for preventing or treating attention deficit hyperactivity disorder (ADHD).
- ADHD attention deficit hyperactivity disorder
- the present invention provides a composition for preventing or treating dementia, which includes an extract of ginseng and proxin as an active ingredient.
- the present invention provides a composition for preventing or treating hyperactivity disorder comprising the extract of quince and proxin as active ingredients.
- the present invention provides a composition for improving cognition, including the extract of quince and proxin as active ingredients.
- the concentration of the proxin is preferably 0.1 to 0.5mM, but is not limited thereto.
- compositions according to the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- Pharmaceutical dosage forms of the compositions of the present invention are in the form of their pharmaceutically acceptable salts. Can also be used, and can also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
- the salt is not particularly limited as long as it is pharmaceutically acceptable, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, acetic formic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, and the like.
- hydrochloric acid sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, acetic formic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, and the like.
- the pharmaceutical composition according to the present invention is an oral dosage form such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, an external preparation such as an ointment, a cream, a suppository and a sterile injection solution, respectively, according to a conventional method. It can be formulated and used in any form suitable for pharmaceutical preparations.
- the preferred dosage of the extract or compound of the present invention varies depending on the subject's age, sex, weight, symptoms, degree of disease, drug form, administration route and duration, but is appropriately selected by a person skilled in the art. Can be. However, for the desired effect, it is recommended that the composition of the present invention be administered at 0.001 to 500 mg/kg body weight per day. Administration may be administered once a day, or may be divided into several times. In addition, the dosage may be increased or decreased depending on age, gender, weight, disease severity, and route of administration. Therefore, the above dosage does not limit the scope of the present invention in any way.
- composition according to the present invention can be administered to a mammal such as a rat, mouse, livestock, or human by various routes such as parenteral or oral, and all modes of administration can be expected, for example, oral, rectal or It can be administered by intravenous, intramuscular, subcutaneous, intrauterine dura mater or intracerebroventricular injection.
- the present invention may be provided as a food additive or a functional food composition of the ginseng extract and the proxin composition of the present invention.
- the food composition according to the present invention may be, for example, chewing gum, caramel products, candies, ice cream, various foods such as sweets, soft drinks, beverage products such as mineral water, and health functional foods including vitamins and minerals.
- the amount of the extract or compound in the food can be added at 0.001 to 99.9% by weight of the total food weight, and in a beverage, it can be added at a rate of 0.001 to 0.1 g based on 100 ml.
- the beverages of the present invention have no particular limitations on other components other than those containing the extracts and compound derivatives as essential components in the indicated proportions, and may contain various flavoring agents or natural carbohydrates, etc. as additional components, as in conventional beverages.
- the functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid And salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonic acid used in carbonated beverages, and the like.
- the ginseng extract and the proxin composition significantly improve cognitive memory and inhibit the production of amyloid plaque in the Alzheimer's dementia model and the APPswe/PS1dE9 double expression Alzheimer's dementia model induced by administration of A ⁇ (1-42). It has been clarified, and the results show the usefulness of the combination of the ginseng extract and the proxin for Alzheimer's disease as a treatment candidate, and it can also be seen that the combination of the ginseng extract and the proxin can be used as a candidate for ADHD treatment.
- 1 is a graph showing the change in the amount of intracellular ROS by Phytochemical treatment
- Figure 2 is a figure showing the combined administration effect of pentagonal ethanol extract (Galla rhois) and / or proxine on cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured by the alteration behavior of the Y-maze test.
- Each group was tested with 16 mice, and each value was the mean ⁇ standard error.
- Figure 3 is a figure showing the combined administration effect of ethanol extract (Galla rhois) and / or proxin of the five-fold on the cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured using a novel object recognition test. Each group was tested with 16 mice, and each value was the mean ⁇ standard error. *P ⁇ 0.01 vs. Saline + ⁇ -amyloid (42-1), #P ⁇ 0.05 vs. Saline + ⁇ -amyloid (1-42) (using Fisher's PLSD test as one-way ANOVA and post-test).
- Figure 4 is a figure showing the combined administration effect of ethanol extract (Galla rhois) and / or proxin of the five-fold on the cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured by observing the finding latency of the water finding test. Each group was tested with 16 mice, and each value was the mean ⁇ standard error.
- Figure 5 is a diagram showing the combined administration effect of ethanol extract (Galla rhois) and / or proxin of the five-fold on the cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured by observing the step-through latency of the passive avoidance test. Each group was tested with 16 mice, and each value was the mean ⁇ standard error.
- Figure 6 is a figure showing the combined administration effect of ethanol extract (Galla rhois) and / or proxin of the five-fold on the cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured using a reference memory test from Morris water maze. Eight mice per group were measured four times daily, each value being the mean ⁇ standard error. *P ⁇ 0.01 vs. Saline + ⁇ -amyloid (42-1), #P ⁇ 0.05 vs. Saline + ⁇ -amyloid (1-42) (using one-way ANOVA for repeat measurements and Fisher's PLSD test as a post-test).
- Figure 7 is a diagram showing the combined administration effect of ethanol extract (Galla rhois) and or proxin of the five-fold on the cognitive memory degradation by ⁇ -amyloid (1-42).
- Cognitive memory was measured using the probe test of Morris water maze. Eight mice per group were measured twice, and each value is the mean ⁇ standard error. *P ⁇ 0.01 vs. Saline + ⁇ -amyloid (42-1), #P ⁇ 0.05 vs. Saline + ⁇ -amyloid (1-42) (using Fisher's PLSD test as one-way ANOVA and post-test).
- Figure 8 is a figure showing the combined administration effect of pentagonal ethanol extract (Galla rhois) and / or proxin on the decrease in cognitive memory by ⁇ -amyloid (1-42).
- mice per group were measured four times a day for three days, and each value is the mean ⁇ standard error.
- Figure 9 is a picture showing the combined pharmacological effects of pentagonal ethanol extract (Galla rhois) and / or proxine on cognitive memory (evaluated by Y-maze test) in APPswe/PS1dE9 double-expressing mice. Each figure represents the mean ⁇ standard error of 10 animals. #P ⁇ 0.05 vs. Saline (One-way ANOVA. Fisher's assessment by post-test).
- Figure 10 is a picture showing the pharmacological effect of co-administration of pentagonal extract (Galla rhois) and/or proxine on cognitive memory (evaluated by Novel object recognition test) of APPswe/PS1dE9 double-expressing mice. Each figure represents the mean ⁇ standard error of 10 animals. #P ⁇ 0.05 vs. Saline (One-way ANOVA. Fisher's assessment by post-test).
- Figure 11 is a picture showing the combined pharmacological effect of the combined administration of ethanol extract (Galla rhois) and / or proxine on the cognitive memory (evaluated by the finding latency of the water finding test) of APPswe/PS1dE9 double-expressing mice. Each figure represents the mean ⁇ standard error of 10 animals. #P ⁇ 0.05, ##P ⁇ 0.01 vs. Saline (One-way ANOVA. Fisher's assessment by post-test).
- FIG. 12 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced hyperlocomotor activity in rats. Each value is the mean ⁇ S.E.M. of 12 rats, *P ⁇ 0.05,**P ⁇ 0.01 vs. Sal + Sal, #P ⁇ 0.05, ##P ⁇ 0.01 vs. Sal + Aroclor 1254
- FIG. 13 is a graph confirming the effect of stigma and/or proxin on increase in Aroclor 1254-induced rearing number in rats. Each value is the mean ⁇ S.E.M. of 12 mice, *P ⁇ 0.05 vs. Sal + Sal, #P ⁇ 0.05 vs. Sal + Aroclor 1254 (one-way ANOVA followed by Fisher's PLSD test)
- FIG. 14 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced changes in the ability to enter and exit from the rat to the central zone.
- Each value is the mean ⁇ S.E.M. of 12 rats, *P ⁇ 0.01 vs. Sal + Sal, #P ⁇ 0.05 vs. Sal + Aroclor 1254 (one-way ANOVA accompanied by Fisher's PLSD test)
- FIG. 15 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced increase in distance traveled from the central zone in mice.
- Each value is the mean ⁇ S.E.M. of 12 rats, *P ⁇ 0.01 vs. Sal + Sal, #P ⁇ 0.05, ##P ⁇ 0.05 vs. Sal + Aroclor 1254
- FIG. 16 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced increase in the number of rats entering the central zone. Each value is the mean ⁇ S.E.M. of 12 rats, *P ⁇ 0.01 vs. Sal + Sal, #P ⁇ 0.05 vs. Sal + Aroclor 1254
- FIG. 17 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced changes in time spent in the central zone in mice. Each value is the mean ⁇ S.E.M. of 12 mice, *P ⁇ 0.05 vs. Sal + Sal, #P ⁇ 0.05 vs. Sal + Aroclor 1254
- FIG. 18 is a graph confirming the effect of stigma and/or proxin on Aroclor 1254-induced learning and memory impairment in a new subject recognition test in rats.
- Each value is the mean ⁇ S.E.M. of 12 rats, *P ⁇ 0.01 vs. Sal + Sal, #P ⁇ 0.05, ##P ⁇ 0.05 vs. Sal + Aroclor 1254 (one-way ANOVA is accompanied by Fisher's PLSD test)
- gallic acid and Fraxin are the most active through screening for antioxidant activity by receiving various known antioxidant activities.
- the compounds used in the antioxidant activity screening of the present invention are as follows A1 to A7.
- A6 and A7 did not show the effect of removing free radicals or regenerating cells.
- A4 has a good effect on both free radical scavenging and cell regeneration, while A3 has good scavenging activity, but has good cell regeneration, so the antioxidant effect of A3 is thought to be due to a different mechanism than free radical scavenging.
- SOD Superoxide dismutase
- catalase assay produced in the cell, or both enzymes has the effect of removing the free radicals coming from the outside are but did not that activity is greatly changed by the aid of H 2 O 2 in H 2 O 2 When A3 was treated before treatment, it was observed that the activity of SOD increased.
- LPO shows a tendency to increase slightly as cells age. In particular, when the cells were exposed to H 2 O 2 , the result of LPO was found to increase the amount of MDA, and it was confirmed that this increase was significantly reduced by the treatment of A3 and A4, and the remaining A1 to A2 and A5 to A7 This activity could not be observed.
- ROS reactive oxygen species
- the present inventors have adopted A3 and A4 as candidates for combination with the five-fold extract from among the A1 to A7 compounds, and since the five-fold extract contains a large amount of the A4 compound, Methyl gallate, the A4 is not additionally added to the five-fold extract, It was decided to further evaluate the effect by further including A3, proxin.
- the concentration of proxin was performed at 0.5 mM, and these concentrations were performed using the DPPH assay for the free radical scavenging activity experiment of proxin.
- various concentrations of proxin (0.02, 0.1 and 0.5) were added to the DPPH solution. mM), and the change in absorbance for 10 minutes was monitored at 517 nm, resulting in free radical scavenging activity of about 10%, about 18%, and about 50% at a concentration of 0.02, 0.1, and 0.5 mM of proxin. It came out and was used in the experiment after 0.5mM.
- the decrease in cognitive memory by A ⁇ was evaluated in 12-week-old mice. ICR mice [Orient Bio Co., Ltd., Gyeonggi, Korea] were purchased and adapted to the experimental animal room for 1 week, and drug administration and cognitive memory evaluation were performed.
- the toxic A ⁇ (1-42) (American Peptide Company, Sunnyvale, CA, USA) and the control substance non-toxic A ⁇ (42-1) (American Peptide Company, Sunnyvale, CA, USA) have 400 pmol as the third ventricle.
- the cognitive memory evaluation was performed 3 days after the administration of A ⁇ .
- Ethanol ethanol extract 500 mg/kg, p.o.
- proxin 0.5 mM
- APPswe/PS1dE9 double-expressing mice The Jackson Laboratory, Bar Harbor, MA, USA
- a cognitive memory evaluation was performed after oral administration of pentagonal ethanol extract (500 mg/kg, p.o.) and/or proxin (0.5 mM) once a day for 3 months to APPswe/PS1dE9 double-expressing mice.
- drugs were administered after the behavioral and cognitive function evaluations were completed to prevent drugs from directly affecting behavior.
- animals were sacrificed to evaluate the degree of A ⁇ accumulation.
- the Y-maze consists of a Y-shaped arm, a black plastic box 25 cm long and 14 cm high and 5 cm wide.
- the mouse was placed at the end of one arm, and the arm was allowed to move freely for 8 minutes.
- the number of times the mouse entered each arm was shot with a video camera.
- the evaluation index of alternating behavior was compared with the control group by acquiring 1 point for all 3 arms.
- the alternation score of the mouse was converted to 100% by dividing the score obtained by the actual mouse by the possible alternation score.
- mice On the first day, the mice were acclimatized by placing them in a 40 cm X 40 cm X 30 cm box and allowing them to move freely for 10 minutes.
- two objects On the second day, two objects were placed in a box and the reaction time for each object was recorded. After 24 hours, one of the two objects was replaced with a new object (novel object), and the reaction time for the novel object was recorded.
- Water finding test is a method of evaluating latent learning and attentional spatial memory. On the first day, let the mouse recognize the nozzle position of the water bottle in the apparatus, and then place it in the apparatus again after 24 hours of water saving to find the nozzle of the water bottle. Then, the time was measured (Finding latency). On the second day, the position of the water bottle and the length of the nozzle were slightly changed, and based on the information acquired on the first day, attention was paid to find a new location.
- the passive avoidance test device consists of two rooms, and is divided into guillotine doors between the two rooms.
- a shock generator is installed on the floor of the room.
- rats were placed in one of the two rooms, acclimatized for 15 seconds, and then the guillotine door was opened at the same time as the room with the mouse was turned on.
- the guillotine door was closed and an electric shock (0.5mA, 5s) was applied to the bottom of the dark room.
- mice were placed in the same device and the time to move from light to dark was measured (step-through latency).
- a cylindrical water tank with a diameter of 97 cm and a height of 60 cm was used.
- 23 ⁇ 2°C water diluted with milk powder was used.
- a transparent platform was installed 2 cm below the surface of the water tank, and four signs were placed outside the water tank.
- the motion trajectory of the mouse was analyzed through a video tracking system (EthoVision, Noldus, The Netherlands).
- mice were placed in a water tank toward the side of the platform where they did not see the platform at five randomly selected starting points.
- the latency of finding the platform after the mouse is placed in the tank is recorded, and when the mouse finds the platform, it remains on the platform for 10 seconds and then moved to the home cage. If the mouse does not find the platform within 60 seconds, the escape latency is recorded as 60 seconds.
- Each trial was conducted four times a day, three days after the administration of ⁇ -amyloid for four days (3-6 days).
- Probe test was conducted 7 days after ⁇ -amyloid administration. After the platform was removed, the number of times the platform had been recorded was recorded by letting the rat swim in the tank for 60 seconds.
- Working memory test was conducted from 8 to 10 days after ⁇ -amyloid administration. Similar to the reference memory test, escape latency was measured by changing the platform location every day. Five trials were conducted per day, and the escape latency of the second to fifth trials was used.
- the animal effect test results are as follows.
- ⁇ -amyloid (1-42) significantly reduced alteration behavior in Y-maze.
- Ojaja extract significantly inhibited the decrease in alteration behavior by ⁇ -amyloid (1-42) (FIG. 2 ).
- the alteration behavior was significantly increased in the case of the combination administration of the extract and the proxin compared to the administration of the embryo alone.
- ⁇ -amyloid (1-42) significantly reduced exploration for novel objects in novel object recognition tests.
- the five-fold extract significantly inhibited the decrease in exploration of novel objects by ⁇ -amyloid (1-42) (FIG. 3 ).
- the reduction of exploration for novel objects by ⁇ -amyloid (1-42) was significantly suppressed by about 6.78% more significantly than when administered with the ginseng alone (FIG. 3 ).
- ⁇ -amyloid (1-42) significantly increased finding latency in a water finding test evaluating latent learning.
- the quince extract significantly suppressed the increase in finding latency caused by ⁇ -amyloid (1-42) (FIG. 4 ).
- the increase in finding latency due to ⁇ -amyloid (1-42) was significantly suppressed by about 11.43% more significantly than when administered with the ginseng alone (FIG. 4 ).
- ⁇ -amyloid (1-42) significantly reduced step-through latency in fear avoidance and passive avoidance tests evaluating memory.
- the five-fold extract significantly suppressed the reduction of step-through latency by ⁇ -amyloid (1-42) (FIG. 5 ).
- the reduction of the step-through latency by ⁇ -amyloid (1-42) was significantly suppressed by about 10.34% more significantly than when administered with the ginseng alone (FIG. 5).
- mice to which ⁇ -amyloid (1-42) was administered had a significantly reduced time to find a safe platform in the tank, and probes to subtract and measure the platform compared to those to which ⁇ -amyloid (42-1) was administered. Even in the test, the time spent in the quadrant where the platform was located was also significantly reduced. Ethanol extracts from five germ significantly suppressed the increase in escape latency by ⁇ -amyloid (1-42) and the decrease in residence time in the quadrant where the platform was located (FIGS. 6 and 7 ).
- ⁇ -amyloid (1-42) induced significantly lower spatial working memory in Morris water maze's working memory test.
- Ojaja extract significantly suppressed the increase in escape latency caused by ⁇ -amyloid (1-42) (FIG. 8 ).
- the increase in escape latency due to ⁇ -amyloid (1-42) was significantly suppressed by about 9.43% more significantly than when administered with the embryonic alone (FIG. 8).
- the five-fold extract significantly increased exploration for novel objects (FIG. 10).
- the exploration was significantly increased by about 9.76% more significantly when administered with the combination of the five-fold extract and proxin than when administered with the five-fold alone (FIG. 10).
- DHD is a disease mainly occurring in children
- immature mice should be used for experiments, and ICR mice [Orient Bio Co., Gyeonggi, Korea] were purchased and adapted to the experimental animal room and mated.
- Aroclor 1254 (18 mg/kg) was orally administered once a day to the mother.
- Gallic acid 100 mg/kg, po
- methyl gallate 100 mg/kg, po
- pentagonal extract from postnatal day 21 to postnatal day 21 until the end of the behavioral experiment
- 500 mg/kg, po) and/or proxine (0.5 mM) were administered once a day.
- mice were placed in a 40 x 40 x 30 cm black acrylic box, and the behavior was measured for 30 minutes using a videotracking system, and the open field was divided into 9 equal parts to set the middle area as the central zone.
- the index of hyperactivity in ADHD was voluntary momentum (distance moved in cm), and the index of impulsive behavior was standing, the time in the central zone, the number of times in the central zone, and the first in the central zone. Time was measured as an indicator. In the open field evaluation, the time spent in the central zone is long and frequent, and the shorter the first time, the more impulsive, and in the opposite case, it is known that there is anxiety. The behavior was measured between 9 am and 6 pm.
- Example 3 The results of Example 3 are as follows.
- Aroclor 1254 significantly induced locomotor activity and increased rearing behavior.
- the administration of quince extract and/or proxin significantly inhibited the increase in hyperlocomotor activity and rearing behavior by Aroclor 1254. ( Figures 12 and 13).
- Aroclor 1254 significantly increased the time spent in the central zone of the open field and the number of times it entered the central zone, and the time of entering the central zone for the first time was significantly shortened, impulsive action was induced.
- Aroclor 1254 significantly reduced the time of interest in novel objects in the novel object recognition test, leading to attention deficit disorder and decreased learning memory.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
- 오배자 추출물 및 프락신을 유효성분으로 포함하는 치매 예방 또는 치료용 조성물.
- 제1항에 있어서, 상기 프락신의 농도는 0.1 내지 0.5mM인 것을 특징으로 하는 조성물.
- 오배자 추출물 및 프락신을 유효성분으로 포함하는 과잉행동장애 예방 또는 치료용 조성물.
- 제3항에 있어서, 상기 프락신의 농도는 0.1 내지 0.5mM인 것을 특징으로 하는 조성물.
- 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선용 조성물.
- 제5항에 있어서, 상기 프락신의 농도는 0.1 내지 0.5mM인 것을 특징으로 하는 조성물.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/299,227 US11253553B1 (en) | 2018-12-18 | 2018-12-18 | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
ES18943563T ES2951919T3 (es) | 2018-12-18 | 2018-12-18 | Composición para mejorar la capacidad cognitiva y prevenir o tratar la demencia y el trastorno por déficit de atención con hiperactividad, que comprende extracto de Galla rhois y fraxina como ingredientes activos |
JP2021535156A JP7066922B2 (ja) | 2018-12-18 | 2018-12-18 | 五倍子抽出物およびフラキシンを有効成分として含む認知機能の改善、認知症および注意欠陥多動性障害の予防または治療用組成物 |
KR1020217005138A KR102246444B1 (ko) | 2018-12-18 | 2018-12-18 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물 |
CN201880100293.7A CN113194972B (zh) | 2018-12-18 | 2018-12-18 | 五倍子乙醇提取物和秦皮苷在制备改善认知能力、预防或治疗痴呆药物中的应用 |
CN202210351314.0A CN114588180B (zh) | 2018-12-18 | 2018-12-18 | 五倍子乙醇提取物和秦皮苷在制备治疗注意缺陷多动障碍的药物中的用途 |
EP18943563.9A EP3900732B1 (en) | 2018-12-18 | 2018-12-18 | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
KR1020207034449A KR102235881B1 (ko) | 2018-12-18 | 2018-12-18 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 |
PCT/KR2018/016129 WO2020130172A1 (ko) | 2018-12-18 | 2018-12-18 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 |
GB2109624.3A GB2596927B (en) | 2018-12-18 | 2018-12-18 | Composition for preventing or treating dementia and improving cognitive ability |
US17/554,052 US11382935B2 (en) | 2018-12-18 | 2021-12-17 | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising Galla rhois extract and fraxin as active ingredients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2018/016129 WO2020130172A1 (ko) | 2018-12-18 | 2018-12-18 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/299,227 A-371-Of-International US11253553B1 (en) | 2018-12-18 | 2018-12-18 | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
US17/554,052 Continuation US11382935B2 (en) | 2018-12-18 | 2021-12-17 | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising Galla rhois extract and fraxin as active ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020130172A1 true WO2020130172A1 (ko) | 2020-06-25 |
Family
ID=71101372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/016129 WO2020130172A1 (ko) | 2018-12-18 | 2018-12-18 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11253553B1 (ko) |
EP (1) | EP3900732B1 (ko) |
JP (1) | JP7066922B2 (ko) |
KR (2) | KR102235881B1 (ko) |
CN (2) | CN113194972B (ko) |
ES (1) | ES2951919T3 (ko) |
GB (1) | GB2596927B (ko) |
WO (1) | WO2020130172A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113194972B (zh) | 2018-12-18 | 2022-09-16 | 金相希 | 五倍子乙醇提取物和秦皮苷在制备改善认知能力、预防或治疗痴呆药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990085202A (ko) | 1998-05-14 | 1999-12-06 | 김기영 | 치매병 예방 및 치료용 생약조성물 |
US20040152760A1 (en) * | 1999-12-30 | 2004-08-05 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
KR20110110638A (ko) * | 2010-04-01 | 2011-10-07 | 김현기 | 오배자 추출물을 유효성분으로 포함하는 인지력 개선 조성물 |
KR20130108821A (ko) * | 2012-03-26 | 2013-10-07 | 김현기 | 오배자 추출물을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물 |
KR20140021882A (ko) * | 2012-08-13 | 2014-02-21 | 주식회사 알엔에스 | 에이엠피케이 활성화 효과를 가지는 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100533777B1 (ko) | 2001-10-26 | 2005-12-06 | 주식회사 안지오랩 | 칠엽수 추출물을 유효성분으로 하는 혈관신생 억제용 조성물 |
KR100507077B1 (ko) | 2002-09-05 | 2005-08-09 | 현대자동차주식회사 | 차량의 주유구 개폐 제어장치 및 방법 |
KR20140022941A (ko) | 2014-02-03 | 2014-02-25 | 윤태병 | 황금동과 그의 제조방법 |
KR20140029510A (ko) * | 2014-02-26 | 2014-03-10 | 김현기 | 오배자 추출물을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물 |
WO2016146026A1 (en) * | 2015-03-13 | 2016-09-22 | China Medical University | Method of increasing d-serine concentration and improving cognitive disorders |
CN105126002A (zh) * | 2015-09-24 | 2015-12-09 | 杨立珍 | 一种防治癫痫的中药制剂及制法 |
MX2018011767A (es) * | 2016-03-28 | 2019-03-28 | Syneurx Int Taiwan Corp | Composiciones que contienen ácidos tánicos y usos de las mismas. |
MX2020005934A (es) | 2017-12-07 | 2020-08-24 | Syneurx Int Taiwan Corp | Metodos de enriquecimiento mejorado para preparar composiciones de acido tanico. |
KR102021281B1 (ko) | 2018-05-25 | 2019-09-16 | 한국 한의학 연구원 | 프락신을 유효성분으로 포함하는 우울증 및 불안장애 예방, 개선 또는 치료용 조성물 |
CN113194972B (zh) | 2018-12-18 | 2022-09-16 | 金相希 | 五倍子乙醇提取物和秦皮苷在制备改善认知能力、预防或治疗痴呆药物中的应用 |
-
2018
- 2018-12-18 CN CN201880100293.7A patent/CN113194972B/zh active Active
- 2018-12-18 ES ES18943563T patent/ES2951919T3/es active Active
- 2018-12-18 KR KR1020207034449A patent/KR102235881B1/ko active IP Right Grant
- 2018-12-18 KR KR1020217005138A patent/KR102246444B1/ko active IP Right Grant
- 2018-12-18 CN CN202210351314.0A patent/CN114588180B/zh active Active
- 2018-12-18 GB GB2109624.3A patent/GB2596927B/en active Active
- 2018-12-18 WO PCT/KR2018/016129 patent/WO2020130172A1/ko unknown
- 2018-12-18 EP EP18943563.9A patent/EP3900732B1/en active Active
- 2018-12-18 JP JP2021535156A patent/JP7066922B2/ja active Active
- 2018-12-18 US US17/299,227 patent/US11253553B1/en active Active
-
2021
- 2021-12-17 US US17/554,052 patent/US11382935B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990085202A (ko) | 1998-05-14 | 1999-12-06 | 김기영 | 치매병 예방 및 치료용 생약조성물 |
US6010702A (en) | 1998-05-14 | 2000-01-04 | Geong Mok Lee | Herbal drug composition for the prevention and treatment of dementia |
US20040152760A1 (en) * | 1999-12-30 | 2004-08-05 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
KR20110110638A (ko) * | 2010-04-01 | 2011-10-07 | 김현기 | 오배자 추출물을 유효성분으로 포함하는 인지력 개선 조성물 |
KR20130108821A (ko) * | 2012-03-26 | 2013-10-07 | 김현기 | 오배자 추출물을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물 |
KR20140021882A (ko) * | 2012-08-13 | 2014-02-21 | 주식회사 알엔에스 | 에이엠피케이 활성화 효과를 가지는 조성물 |
Non-Patent Citations (1)
Title |
---|
WHANG , WAN KYUNN: "Natural compounds, fraxin and chemicals structurally related to fraxin protect cells from oxidative stress", EXPERIMENTAL AND MOLECULAR MEDICINE, October 2005 (2005-10-01), XP008082986 * |
Also Published As
Publication number | Publication date |
---|---|
GB2596927B (en) | 2022-04-06 |
KR102235881B1 (ko) | 2021-04-02 |
CN114588180A (zh) | 2022-06-07 |
GB202109624D0 (en) | 2021-08-18 |
CN113194972A (zh) | 2021-07-30 |
KR20200143490A (ko) | 2020-12-23 |
US11382935B2 (en) | 2022-07-12 |
GB2596927A (en) | 2022-01-12 |
EP3900732A4 (en) | 2022-05-04 |
EP3900732C0 (en) | 2023-06-14 |
EP3900732A1 (en) | 2021-10-27 |
ES2951919T3 (es) | 2023-10-25 |
KR20210022161A (ko) | 2021-03-02 |
CN113194972B (zh) | 2022-09-16 |
JP7066922B2 (ja) | 2022-05-13 |
CN114588180B (zh) | 2023-04-28 |
JP2022513304A (ja) | 2022-02-07 |
EP3900732B1 (en) | 2023-06-14 |
KR102246444B1 (ko) | 2021-04-29 |
US20220105139A1 (en) | 2022-04-07 |
US11253553B1 (en) | 2022-02-22 |
US20220040240A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220160798A1 (en) | Method for producing spirulina extract, and spirulina extract-containing pharmaceutical composition and health functional food for improving cognitive ability | |
WO2018084528A1 (ko) | 항산화 및 피부 개선용 조성물 | |
WO2010036052A2 (ko) | 4-o-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물 | |
KR100540369B1 (ko) | (-)에페갈로카테킨 갈레이트 화합물을 포함하는 중증 무력증, 위장관과 방광평활근 무력증 및 녹내장 질환의 치료 또는 예방용 약학적 제제와 기억력 촉진를 위한 약학적 제제 | |
WO2020130172A1 (ko) | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물 | |
KR20170003395A (ko) | 고수 추출물을 유효성분으로 하는 치매 예방 또는 치료용 약학적 조성물 | |
WO2024106716A1 (ko) | 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용 조성물 | |
US10799551B2 (en) | Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients | |
WO2022102801A1 (ko) | 오배자 추출물 및 암피실린을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 및 치료용 조성물 | |
CN112043700B (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用 | |
WO2018080158A1 (ko) | 좁은잎보리장나무 추출물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2019203509A1 (ko) | 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물 | |
KR101140583B1 (ko) | 클라도니아 마실렌타 퍼플 균체 또는 이의 배양 추출물, 및/또는 이로부터 유래한 비루로퀴논을 포함하는 아세틸콜린에스테라제 저해제 | |
WO2014038878A2 (ko) | 머스크랫의 사향을 함유하는 뇌신경세포 보호 및 뇌질환 예방, 완화 또는 치료용 조성물 | |
WO2024058552A1 (ko) | 칸나비노이드를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 및 이의 용도 | |
WO2011132831A1 (ko) | 글루타민의 우울증 예방, 치료 또는 진단을 위한 용도 | |
GB2596491A (en) | Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract | |
WO2020231024A1 (ko) | 고시페틴을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
WO2022075540A1 (ko) | 글루타민을 유효성분으로 함유하는 뇌손상 및 경도 인지장애의 예방, 개선 또는 치료용 조성물 | |
WO2016064009A1 (ko) | 라말린을 함유하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2018155956A1 (ko) | 백합 비늘줄기 추출물을 포함하는 인지장애의 예방 또는 치료용 약학 조성물 | |
WO2021085741A1 (ko) | 번행초를 유효성분으로 포함하는 알츠하이머성 치매 개선 또는 치료용 조성물 | |
WO2020159044A1 (ko) | 뎁손을 유효성분으로 함유하는 인지기능 장애의 예방 또는 치료용 조성물 | |
KR20230141647A (ko) | 백작약 추출물 및 그의 지표성분을 포함하는 기억력 및 인지기능 장애 예방 또는 치료용 조성물 | |
KR20170139380A (ko) | 모노아세틸디아실글리세롤 화합물을 함유하는 집중력 향상 또는 인지기능 장애 질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18943563 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20207034449 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021535156 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 202109624 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20181218 |
|
ENP | Entry into the national phase |
Ref document number: 2018943563 Country of ref document: EP Effective date: 20210719 |